The binding of thrombin to fibrin is thought to be an important mechanism by which thrombi exhibit procoagulant activity; however, the extent to which other procoagulants are associated with thrombi has not been previously defined. This study was designed to determine whether clotting factors other than thrombin are bound to whole-blood clots and can thereby contribute to significant procoagulant activity. Clots formed in vitro from human blood exhibited minimal thrombin activity when incubated in plasma depleted of vitamin K-dependent factors by barium-citrate adsorption, as indicated by increases in the concentration of fibrinopeptide A (FPA), a marker of fibrin formation, to 72 nM after 30 min. Incubation of clots in barium-absorbed plasma repleted with 0.9 ,uM human prothrombin under the same conditions resulted in marked increases in the concentration of FPA (> 1,000 nM) and clotting by 30 min. The increases in FPA were attributable to activation of the added prothrombin by clot-associated Factor Xa, judging from concomitant increases in the concentration of prothrombin fragment 1.2. Similar results were obtained with thrombi induced in the axillary arteries of dogs by vascular injury and incubated with plasma in vitro. Activation of prothrombin was inhibited in a dose-dependent manner by tick anticoagulant peptide, a direct inhibitor of Factor Xa, at concentrations of 0.5-5.0 gM. Clot-associated Factor Xa activity was resistant to inhibition by anti-thrombin III, judging from the lack of inhibition of prothrombin activation during incubation of clots in plasma containing heparin pentasaccharide, an anti-thrombin 111-mediated inhibitor of Factor Xa. Thus, the activity of Factor Xa appears to be an important determinant of the procoagulant activity of whole-blood clots and arterial thrombi, and is resistant to inhibition by anti-thrombin III-dependent inhibi-
Introduction
It has been suggested that the propensity of thrombi to induce activation ofthe coagulation system plays an important role in the recurrence of thrombosis after thrombolysis and in the propagation ofthrombi. One potential contributorto the procoagulant activity of thrombi is the persistence of activity of thrombin bound to fibrin ( 1-3). Thrombin appears to bind to thrombi in vivo, judging from the thrombin activity associated with thrombi recovered from patients at the time of vascular surgery (1) . Thrombin bound to fibrin has been shown to induce continued formation of fibrin and to be relatively protected from inhibition by anti-thrombin III or anti-thrombin III-heparin complex (2) (3) (4) . Because thrombin activates Factors V and VIII, even minimal thrombin activity associated with thrombi may play an important role in potentiating activation ofthe coagulation system. However, the extent to which procoagulants other than thrombin are associated with thrombin and may induce procoagulant activity has not been defined.
In addition to fibrin, thrombi formed in vivo contain varying amounts of platelets, other circulating blood cells, and other adhesive proteins, including fibronectin. It is likely that platelets contribute to the procoagulant properties of thrombi in an important way by providing binding sites for the Factor Xa/Va complex on their membrane surface (5) . The Xa/Va complex activates prothrombin, and when bound to phospholipid is relatively protected from inhibition by anti-thrombin III (6) . In addition, the Factor IXa/ VIIIa complex may bind to platelets. Thus, the procoagulant activity ofthrombi formed in vivo may be attributable to the activity of Factor Xa or IXa associated with the thrombus, as well as to thrombin bound to fibrin. This study was designed to determine whether clotting factors other than thrombin are bound to whole-blood clots formed in vitro and thrombi formed in vivo, and to define the extent to which the activity of other clotting factors contribute to the procoagulant activity of thrombi.
Methods
Material. Fibrinogen was purchased from Kabi Vitrum (Kabi L fibrinogen; Kabi Vitrum, Fredrickstown, OH) or prepared as described by Blomback (7) . Fibrinogen was depleted ofplasminogen by lysine-sepharose affinity chromatography. Human Factor X and prothrombin were isolated and purified from pooled citrated plasma, as previously described (8) . Thrombin was prepared from purified human prothrombin by activation with Taipan snake venom, and isolated by cation exchange chromatography on an Amberlite CG-50 column. The thrombin preparation contained > 90% a-thrombin, as determined by migration on reduced and nonreduced SDS-PAGE and staining by Coomassie blue.
Activated Factor X (Xa)' was prepared by incubation of human Factor X with purified Factor X coagulant protein from Russell viper venom at a 1: 1,000 ratio by weight in 0.02 M Hepes, 0.15 M NaCl, 0.002 M CaCl2, pH 7.4, at 37°C for 30 min. Complete activation of Factor X prepared under these conditions was confirmed by absence of 1. Abbreviations used in this paper: FPA, fibrinopeptide A; PPACK, D-Phe-L-Pro-L-Arg-Chloromethylketone, S-2222, N-benzoyl-L-isoleu-zymogen Factor X, as determined by migration on SDS-PAGE and staining with Coomassie blue. Fresh-frozen plasma was purchased from the American Red Cross (St. Louis, MO). Whole-blood, as well as platelet-rich and platelet-poor plasma, were from blood samples obtained by venipuncture from healthy, nonhospitalized volunteers who had not taken aspirin or any aspirin-containing medications within the previous 72 h. Plasma was prepared from blood collected into 3.8% sodium citrate (vol ratio 9:1 ) and subjected to centrifugation at 300 g for 15 min for platelet-rich plasma, or 1,500 g for 30 min for plateletpoor plasma.
Aprotinin and recombinant hirudin (RHV2 variant) were obtained from Sigma Chemical Co. (St. Louis, MO). Heparin sodium was purchased from LyphoMed (Rosemont, IL). D-Phe-L-Pro-L-Arg-chloromethylketone (PPACK) was purchased from Calbiochem (La Jolla, CA) (9) . Recombinant tick anticoagulant peptide (TAP), a specific Factor Xa inhibitor, was provided by Merck, Sharp, & Dohme (West Point, PA) (10, 11) . Heparin pentasaccharide, an anti-thrombin IIIdependent specific inhibitor of Factor Xa, was provided by Choay (Paris, France) ( 12) . The chromogenic substrate for Factor Xa activ-
HCl (S-2222), was purchased from Chromogenix (Franklin, OH).
Preparation ofplasma and whole-blood clots. Whole-blood clots were prepared by modification ofthe method ofChandler ( 13 ). Blood was drawn through a 19-gauge needle and then transferred in 1-ml aliquots to lengths oftygon tubing. The tygon tubing was connected to form a closed circle and rotated at 370C for 1 h. The clot was then removed and washed extensively with saline.
Plasma clots were prepared from citrated platelet-rich or plateletpoor plasma by addition ofCaC12 and thrombin at final concentrations of 25 mM and 2 nM, respectively, followed by incubation at 370C for c 30 min. The clots were formed on stainless steel wires, retracted, and washed three times in 1-ml aliquots of0.02 M Na2PO4, and 0. 15 NaCl, pH 7.4. Complete removal of adherent thrombin associated with plasma and whole-blood clots was confirmed by lack of amidolytic activity of the final wash buffer toward the chromogenic substrate S-2238 (Kabi Vitrum, Fredrickstown, OH), a substrate for thrombin.
Preparation ofbarium citrate-adsorbed plasma. Plasma depleted of vitamin K-dependent factors was prepared by addition of 100 mM BaCl2 to pooled citrated plasma at 4°C for 60 min, followed by centrifugation to separate the precipitate. The supernatant was recovered and additional barium chloride precipitate was allowed to form. The supernatant plasma was then collected and dialyzed exhaustively against 0.15 M NaCl and 0.0 12 M sodium citrate, pH 6 .0. The barium citrateadsorbed plasma (barium-adsorbed plasma) was stored as 1.0-ml aliquots at -70°C and thawed at 37°C immediately before use.
Thrombi formed in vivo. Thrombi were recovered from dogs with induced arterial thrombosis. All procedures were conducted according to the guiding principles ofthe American Physiologic Society and were approved by the Animal Studies Committee at Washington University (St. Louis, MO). Mongrel dogs weighing [22] [23] [24] [25] kg were anesthetized intravenously with sodium pentobarbital (30 mg/kg), intubated, and ventilated with oxygen-enriched room air. Body temperature was maintained with a heating pad. The axillary artery was exposed, side branches were ligated, and a 20-MHz Doppler-flow probe was placed proximal to the intended site of thrombosis. A platelet-rich thrombus was formed by applying direct anodal current (300 ,uA) to an indwelling transluminal electrode for 90 min or until occlusion occurred. The current was then stopped, the vessel ligated, and the thrombus carefully removed from the vessel and placed in saline. The thrombus was extensively washed, as described above, before incubation with plasma.
Characterization ofthrombin-dependent clot-associated procoagulant activity. Clot-associated thrombin activity was Radioimmunoassay ofFPA. Plasma was adsorbed with bentonite before assay for FPA, as previously described ( 16, 17) . The concentration of FPA was determined with a polyclonal antisera-based commercial radioimmunoassay (Byck Sangtek, Dietzenbach, Germany).
ELISA for prothrombin fragment 1.2. The ELISA for prothrombin fragment 1 
Results
Thrombin compared with Xa activity of whole-blood clots. To determine the extent of thrombin activity associated with whole-blood clots, washed clots were incubated in recalcified barium-adsorbed plasma, and the rate of thrombin-catalyzed conversion of fibrinogen to fibrin I was characterized by serial measurement of plasma concentrations of FPA. Increases in FPA in this system reflected thrombin activity associated with the clot, since other vitamin K-dependent factors had been depleted by barium adsorption. As shown in Fig. 1 , wholeblood clots induced modest increases in the concentration of FPA to 72 nM after a 30-min incubation (n = 2), consistent with minimal clot-associated thrombin activity.
To characterize the extent of Factor Xa activity associated with whole-blood clots, washed clots were incubated in barium-adsorbed plasma to which 0.9 yM purified human prothrombin was added. FPA did not increase in recalcified barium-adsorbed plasma containing prothrombin incubated with purified Factor Xa coagulant protein. This result is consistent with complete depletion of Factor X in the plasma; thus, activation of prothrombin reflected the activity of Factor Xa associated with the whole-blood clot. As shown in Fig. 1 To further confirm the role of Factor Xa activity in inducing the marked activation of prothrombin that was observed, whole-blood clots were incubated in recalcified barium-adsorbed plasma repleted with human prothrombin in the presence of recombinant TAP, a specific inhibitor of Factor Xa. As shown in Figs. 1 and 2 , incubation of whole-blood clots in plasma containing TAP markedly attenuated in a dose-dependent manner the increases in FPA and prothrombin fragment 1.2 induced, compared with those observed in the absence of inhibitor. However, activation of prothrombin was not abolished, even at a concentration of 5 AsM TAP, as indicated by minimal increases in the concentration of prothrombin fragment 1.2 and FPA.
To determine whether both thrombin and Factor Xa activity were necessary for clot-bound Factor Xa to induce prothrombin activation, whole-blood clots were initially incubated in a PBS with 1 U!/ml of recombinant hirudin. The clots were washed to remove unbound hirudin and then incubated in recalcified barium-adsorbed plasma. Preincubation of the clots with hirudin abolished thrombin activity, judging from Whole-blood clots were also incubated with recalcified barium-adsorbed plasma repleted with 0.18 nM Factor X, under identical conditions described above for incubation with prothrombin-repleted plasma, to determine whether activation of Factor X was induced. Thrombin andfactor Xa activity ofthrombiformed in vivo.
To determine whether thrombi formed in vivo exhibit Factor Xa activity similar to that ofwhole-blood clots formed in vitro, thrombi were recovered from a preparation of axillary artery injury in dogs. Thrombi were extensively washed and handled in a manner identical to the whole-blood clots prepared from human blood in vitro. As shown in Fig. 3 Response ofclot-boundXa activity to specific inhibitors. To define the response of clot-associated Xa activity to inhibition, TAP and heparin pentasaccharide were incubated with wholeblood clots in the recalcified barium-adsorbed plasma prothrombin system. Both inhibitors were added to the plasma just before recalcification and addition of the whole-blood clots. Heparin pentasaccharide, which acts by catalyzing antithrombin III-mediated inhibition ofFactor Xa, did not inhibit clot-associated Xa activity even at a relatively high concentration (5 ,tg/ml), judging from the increases in the concentrations of FPA (Fig. 4) after 10 min of incubation. Concentrations ofprothrombin fragment 1.2 were > 3 nM after 10 min of incubation of clots with heparin pentasaccharide, confirming activation of prothrombin. The increases in FPA were attenuated by TAP in a dose-dependent manner, but relatively high concentrations ofTAP (5 ,um) were required (Fig. 5) . To determine whether the limited efficacy of heparin pentasaccharide was attributable to the association of Factor Xa activity with clot, 0.25 or 0.5 nM purified human Factor Xa was added to barium-adsorbed plasma repleted with prothrombin and incubated with 1.0 and 5.0 ,g/ml ofheparin pentasaccharide in the absence of clot. The concentrations of Factor Xa added were selected to induce increases in the concentration of FPA similar to those observed after 10 min ofincubation ofwhole-blood clots in this plasma system under identical conditions. Heparin pentasaccharide, at the concentrations used, markedly attenuated the increases in FPA induced by free Factor Xa (Fig. 4) Factor Xa activity ofplatelet-rich versus platelet-poor clots. To characterize the extent to which Factor Xa activity was attributable to platelets, clots were prepared from platelet-rich and platelet-poor plasma and incubated in recalcified bariumadsorbed plasma with or without repleted prothrombin. Concentrations of FPA increased only minimally during incubation of these clots in recalcified barium-adsorbed plasma alone ( Fig. 7) , although slightly greater increases were observed with platelet-poor compared with platelet-rich clots. In contrast, incubation ofclots with recalcified barium-adsorbed plasma after repletion with 0.9 gM prothrombin resulted in marked increases in the concentration of FPA, consistent with extensive activation of prothrombin. As shown in Fig. 7 , platelet-rich clots induced more marked increases in the concentration of FPA than did platelet-poor clots.
Association of Factor Xa with fibrin clots. To determine whether factor Xa activity associated with platelet-poor clots was attributable to binding of factor Xa to fibrin, increasing 
Discussion
The results ofthis study indicate that the procoagulant properties of thrombi are in part attributable to the activity of Factor Xa bound to the thrombus. Our results confirm that thrombin binds to fibrin and remains enzymatically active. However, when the clot-bound thrombin activity is inhibited by hirudin, marked activation ofprothrombin in plasma still occurs. Thus, clot-bound Factor Xa activity is sufficient, even in the absence of thrombin, to exert significant procoagulant activity. The presence of clot-associated Factor Xa suggests that inhibition of clot-associated procoagulant activity by thrombin-specific inhibitors will be ineffective in preventing continued activation ofprothrombin. However, inhibition ofFactor Xa may attenuate clot-associated procoagulant activity. Recent results demonstrating the efficacy of TAP in preventing reocclusion after thrombolysis are consistent with this hypothesis ( 19) .
An unexpected finding of this study was that Factor Xa appears to bind to fibrin in clots. An interaction of Xa with fibrin is consistent with the observation that fibrin II monomer attenuates anti-thrombin III-mediated inhibition of Factor Xa (4). Because the association of Factor Xa with fibrin clots that we observed may be in part attributable to nonspecific protein trapping, additional studies characterizing the association of Factor Xa with fibrin monomer will be necessary to determine whether a specific binding of Xa to fibrin occurs, as has been observed with thrombin ( 1-3) .
Although clot-bound thrombin activity induces fibrin formation, the increases in the concentration ofFPA are relatively modest ( 1, 3) . Thus, it has been assumed that activation ofthe coagulation cofactors V and VIII by thrombin accounts for the marked procoagulant properties ofthrombi. However, the role of other clot-associated factors in the induction of procoagulant activity by clots formed in vivo has not previously been defined. In the current study, whole-blood clots formed in vitro as well as thrombi recovered after arterial injury in vivo exhibited, in addition to thrombin activity, Factor Xa activity that was sufficient to induce marked activation of prothrombin. The extent of prothrombin activation induced by Factor Xa is significantly greater than that associated with thrombin, judging from the> 10-fold greater increase in EPA induced by Factor Xa activity compared with clot-bound thrombin activity (Fig. 1) . Because thrombin activates Factors V and VIII, it is possible that clot-associated thrombin and Factor Xacould act synergystically by inducing prothrombin activation leading to thrombin-mediated activation of cofactors V and VIII, which would potentiate procoagulant activity. These findings have important therapeutic implications because one of the rationales for the use of thrombin-specific anticoagulants is their greater efficacy, compared with heparin-anti-thrombin III, in inhibiting clot-bound thrombin activity. Our findings suggest that thrombin-specific therapy may be effective only as long as it is continued. The persistence ofFactor Xa activity is likely to induce continued activation of prothrombin despite potent inhibition of thrombin. This may also account for the recent observation of recurrent thrombosis after discontinuation of heparin in patients with unstable angina (20) .
We were unable to demonstrate significant Factor IXa or VIIa activity associated with the whole-blood clots formed in vitro. Nonetheless, we cannot exclude the possibility that the activity ofthe IXa/ VIIIa or VIIa/tissue factor complexes contributes to clot-induced procoagulant activity in vivo. Activaticn of Factor X by either of these complexes could increase local Factor Xa concentrations to an even greater extent than that which we observed.
Although maximal activation of prothrombin requires formation of a complex of Factor Xa and Factor Va on phospholipid membranes (6), our findings suggest that Factor Xa associated with fibrin clots exhibits procoagulant activity as well (Fig. 8) . Additional studies to define the enzymatic activity of Factor Xa bound to fibrin, relative to free Factor Xa, and that associated with Factor Va in the prothrombinase complex, should further clarify the potential importance of Factor Xa bound to fibrin. The finding that platelet-rich clots induce marked activation of prothrombin is consistent with the importance ofthe factor Xa/Va complex bound to platelets in the procoagulant activity of whole-blood clots (Fig. 7) . This may be particularly relevant to the platelet-rich thrombi formed in the arterial system under conditions of high shear stress (20) .
Recent studies with TAP in animals indicate that inhibition of Factor Xa is effective in attenuating thrombosis in response to arterial injury and recurrent thrombosis after coronary thrombolysis ( 19, 21 ) . Patients treated with tissue-type plasminogen activator for acute myocardial infarction exhibit increases in prothrombin activation consistent with increases in Factor Xa activity as well (22) . Our results are consistent with these findings and indicate that Factor Xa-induced activation of prothrombin is likely to play a pivotal role in recurrent thrombosis after thrombolysis. Maximal inhibition ofthe procoagulant activity of thrombi may require inhibition of both thrombin and Factor Xa. Judging from the results of the current study, antithrombin III-independent inhibitors may be more effective in inhibiting clot-induced procoagulant activity, because both thrombin and Factor Xa bound to clot appear to be relatively protected from inhibition by anti-thrombin III (4) . Direct inhibition of Factor Xa with TAP was effective in inhibiting Xa associated with clots; however, the effectiveness of this inhibitor may be limited by its slow-binding kinetics. We found that the concentrations of TAP required to inhibit clot-associated Xa procoagulant activity when TAP was not preincubated with the clot were higher than those necessary to inhibit free Xa under the same conditions. However, fibrin II monomer did not attenuate the efficacy ofTAP when the inhibitor was preincubated with Xa before the extent of inhibition was characterized (Fig. 6) .
In summary, whole-blood clots, particularly when platelet rich, appear to induce activation of the coagulation system by at least two phenomena: one is ascribable to the activity of thrombin bound to fibrin, and the other to clot-associated Xa activity. Both clot-associated thrombin and Factor Xa appear to be relatively protected from inhibition by anti-thrombin III or heparin-anti-thrombin III. These results are consistent with the relative attenuation by fibrin monomer of anti-thrombin III-dependent inhibition of Factor Xa, as demonstrated by Hogg and Jackson (4) . Factor Xa activity associated with whole-blood clots induces thrombin formation de novo, even when clot-bound thrombin is inhibited. Clot-associated Factor Xa activity can be inhibited by specific inhibitors such as TAP, and its inhibition may provide an effective means ofpreventing recurrent thrombosis induced by residual thrombi in the arterial circulation.
